Catalyst Pharmaceuticals' controversial $375,000 rare autoimmune disease drug now won't face generic competition from Teva ...

It was a busy week in the biotech sector, with many regulatory and pipeline updates. Neumora Therapeutics NMRA plummeted on ...

Catalyst stock gains 17% as it settles Firdapse patent litigation with Teva protecting the drug's exclusivity in the United ...

Despite weathering significant criticism from lawmakers and patient groups over the steep cost of its rare disease med ...

Global Spinal Cord Injury Therapeutics Market is estimated to valued US$ 7.4 billion in 2023 & expected to exhibit CAGR of 5.4% during forecast period 2023-2030 Mr. Shah Coherent Market Insights Pvt.

The global chronic wound care market is poised for significant growth, with a projected rise at a Compound Annual Growth Rate (CAGR) of 3.8% from 2023 to 2033. The market value is forecasted to ...

Ten companies bucked an overall bearish market sentiment, booking significant gains during the last trading day of the week.

In this article, we are going to take a look at where Teva Pharmaceutical Industries Ltd (NYSE:TEVA) stands against the other stocks. A wave of selling gripped Wall Street this Friday, pushing ...

Amicus Therapeutics' shares are down 15% recently despite a profitable Q3 2024 and raised FY2024 outlook. Click here to find ...

TEL AVIV, Israel, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the ...

Teva Pharmaceutical Industries Limited (TEVA ... We’re talking disease prediction, hyper-personalized marketing, and automated logistics that streamline everything. This isn’t a maybe ...

As 2025 approaches, the digital marketing landscape is set to experience seismic change. Emerging technologies, particularly artificial intelligence, and shifting consumer expectations mean ...